Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Recruiting

Study on Glucose Use in Adults with Severe Burns

Registered drug
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial focuses on patients with severe burns. The study aims to understand how the body distributes glucose during the first four days of treatment for adults who have experienced severe burns. The treatment involves using an injectable solution called GLUCOSE 30% PROAMP, which is administered through an IV injection or infusion. The purpose of the study is to describe the average initial volume of glucose distribution in these patients.

Participants in the study will receive the glucose solution, and their blood glucose levels will be measured at specific times to observe how the glucose is distributed in the body. This involves taking a blood sample, injecting a small amount of glucose, and then measuring the blood glucose level again after a short period. The study will also monitor other factors such as the volume of blood in the chest and the amount of water in the lungs, using a special device called PiCCO.

The study will last for four days, during which various measurements will be taken to gather information about the body's response to the glucose treatment. The goal is to improve understanding of how glucose is distributed in patients with severe burns, which may help in managing their treatment more effectively in the future.

The research process

The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial assessment

    Upon joining the study, an initial assessment is conducted to confirm eligibility. This includes verifying that the patient is over 18 years old, has burns covering at least 30% of the body surface area, and was admitted within 8 hours post-burn.

    Consent is required, either directly from the patient or from a trusted person if the patient is unable to provide it.

  2. Step 2

    Glucose administration

    A solution called glucose 30% proamp is administered. This is a solution for injection given through an intravenous (IV) line.

    A bolus of 5 grams of glucose is injected into a central venous line over 30 seconds.

  3. Step 3

    Blood glucose measurement

    A reference blood glucose level is measured using an arterial blood sample taken from an arterial catheter.

    Three minutes after the glucose injection, a second blood glucose level is measured. The difference between these two levels is recorded.

  4. Step 4

    Calculation of initial distribution volume of glucose (IDVG)

    The IDVG is calculated using a specific formula: IDVG = 24.4 x e(-0.0298 * d[glu]) + 2.7 in liters, where d[glu] is the difference in blood glucose levels measured in mg/dl.

  5. Step 5

    Additional measurements

    At the same time as the IDVG measurement, other parameters are assessed, including intra-thoracic blood volume (ITBV) and extra-vascular lung water (EVLW) using a device called PiCCO.

    Body surface area is assessed using the Wallace method, and water intake and output balance are monitored.

  6. Step 6

    Monitoring and follow-up

    The primary objective is to describe the mean values of the initial volume of glucose distribution during the first four days of management.

    Secondary endpoints include monitoring in-hospital mortality and arterial blood glucose levels before and after glucose bolus injection.

Who can join the trial?

6 criteria

  • Patients must be over 18 years old.
  • Patients must be hospitalized with burns covering at least 30% of their body surface. This means a large part of their skin is affected by the burn.
  • The burns must be caused by heat, such as fire or hot liquids.
  • Patients must be treated at the CHR Metz-Thionville burn center within 8 hours after the burn injury.
  • Patients must be part of a social security scheme, which is a system that provides health coverage.
  • Written consent must be obtained from the patient. If the patient cannot give consent, a trusted person, family member, or relative can provide it. If no one is available, emergency inclusion is possible.

Who cannot join the trial?

5 criteria

  • Patients who do not have severe burns cannot participate. Severe burns are serious injuries to the skin caused by heat, chemicals, electricity, or radiation.
  • Patients who are not within the specified age range cannot participate. The age range includes children and adults.
  • Patients who are not part of the specified clinical trial groups cannot participate. This means the study is looking for specific types of patients.
  • Patients who are not male or female cannot participate. The study includes both men and women.
  • Patients who are not considered part of a vulnerable population cannot participate. A vulnerable population includes groups of people who may need special protection or care.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Glucose is used in this trial to study how it is distributed in the body of severely burned adults during the first four days of treatment. The focus is on understanding the initial volume of glucose distribution, which can help in managing the patient's condition effectively.

What is already known about the treatment

Glucose Solution – This medication is administered intravenously, meaning it is delivered directly into the bloodstream through a vein. It is currently being studied in clinical trials for its role in managing severe burns, specifically focusing on the distribution volume of glucose in the body. The main therapeutic indication is to support metabolic needs and fluid balance in patients with severe burns. At the molecular level, glucose provides energy to cells and helps maintain normal cellular function. It is classified pharmacologically as a carbohydrate and is essential for energy production in the body.

Investigated diseases

Severe burns – Severe burns are injuries to the skin and underlying tissues caused by heat, chemicals, electricity, or radiation. They can damage multiple layers of skin and may extend to muscles and bones. The severity of a burn is determined by its depth and the percentage of body surface area affected. Severe burns can lead to significant fluid loss, infection, and complications affecting other organs. The healing process can be prolonged and may result in scarring and loss of function in the affected areas. Management often involves specialized care to support healing and prevent complications.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IITrial ID2024-513874-23-00Protocol code2023-03-CHRMTEstimated enrolment15 patientsSponsorCentre Hospital Region Metz Thionville

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).